Log in
Body Sensor Networks (BSN) research developed novel sensing algorithms and technology suitable for on-body pervasive sensing suitable for healthcare, well-being and sporting applications. The main impact includes:
A ground-breaking range of innovative sensor products — the EPIC Sensors — has been developed and marketed world-wide by Plessey Semiconductors Ltd. The EPIC Sensors allow contact-free measurements of electric phenomena, initially aimed at the health, sports and automotive markets. They operate on the non-invasive, low-cost, generic, award-winning Electric Potential Sensor (EPS) technology invented and developed at Sussex as a spin-off from fundamental low-temperature physics research. Income to the University from licence fees, costs and royalties started during 2012. Sustained industry engagement with key strategic partners in the medical, forensic, security, materials testing and geophysics sectors, including government organisations, industry and academia, is leading to a wider awareness and adoption of this novel technology.
Reliable and timely measurements are vital for innovation, trade, environmental protection and quality of life. University of Bedfordshire work with measurement systems was already established in 1993 with commercially sponsored work to develop and patent sensors for rapid toxicity assessment in the water industry. Biosensor technologies provide approaches to development and application of cost effective devices for measurement at the point of need in many fields of application and the university's Sensor Research Group has continued to work with industry to develop robust (bio)sensor systems to address business and society needs — particularly with respect to environmental protection, health and wellbeing.
The first commercial electronic nose (aka e-nose) instruments were designed, developed and built by researchers in Warwick's School of Engineering in the 1990s, and commercialized by [text removed for publication]
Warwick's patents in chemical sensing also led in 2008 to the creation of a spin-out company, Cambridge CMOS Sensors Ltd (CCS), which provides low-cost low-power gas-sensing technology and is already established in the gas-sensing market.
The smart sensors and instrumentation developed as a result of the pioneering research in artificial olfaction and chemical sensing have had economic impacts across a wide range of sectors, in particular in food quality, healthcare and consumer electronics. The two companies employ around 100 people and the thousands of e-nose instruments sold help quality assurance of foods, beverages and are now being deployed in hospitals for bacterial detection.
Today's global telecom systems are powered by technology developed at the University of Glasgow. This technology has been utilised, endorsed and developed by a series of internationally successful companies, facilitating multimillion pound investment from across Europe and the USA for the companies.
Gemfire Europe acquired the University of Glasgow IP and technology and between 2008 and 2012 launched a range of `green' products with reduced power consumption. The company's revenues reached $12m annually and in 2013, Gemfire was one of the world's top five planar lightwave circuit companies. Gemfire was bought by Kaiam, one of the world's market-leading optical networking companies in April 2013, stimulating further innovation and investment in the production of high-speed components for the global data networking market.
Fifteen years of research in advanced Lab-on-a-Chip technologies at the University of Glasgow has led to three spin-out companies: Mode-Dx, Clyde Biosciences and SAW-Dx. Since 2008 these companies have developed a range of products and services for the diagnostic screening of chronic diseases, for the detection of acute infections and for improving the drug discovery process. The three companies have secured a total of £2.3M in venture funding and secured key strategic collaborations with stakeholders including industry partners and the NHS.
Medipix-based detectors are the best pixelated X-ray detectors available on the market and are commercialised by PANalytical under the brand name PIXcel. At the core of PIXcel is the Medipix2 chip, which was developed around a photon counting breakthrough conceived by the Medipix collaboration and is unique in its adaptability, high spatial resolution, high dynamic range and low noise. This product is the direct result of an exclusive license and a collaboration agreement between PANalytical and the Medipix collaboration, coordinated by CERN and comprising a further sixteen leading physics research institutes in Europe. The University of Glasgow is the only UK institution to be one of the four founding members of the Medipix1 collaboration.
NIBEC connected health related research over the past 20 years has led to three high value spin- out companies. Their success is based on exploitation of over 35 NIBEC patents in medical sensors and electro-stimulation devices. Together these companies are currently valued at almost £100m, employ over 150 skilled people and have engineered medical innovations that have had global beneficial impact on health costs and patients' lives over these past four years. Our research is closely linked with international partners, commercial and clinical, has impacted local government policy through our leadership of the European Connected Health Alliance and has resulted in the £5m industry-focussed Connected Health Innovation Centre established at NIBEC.
The development of unique computer simulation tools has profoundly influenced the design and manufacture of silicon chips fuelling the $300 billion per year semiconductor industry. A pioneer of statistical variability research, Professor Asen Asenov developed understanding and awareness of statistical variability in the nanoscale transistors which make up all silicon chips. Gold Standard Simulations (GSS) was created in 2010 and by 2012-13 had grown revenue from services and licensing to $1million. GSS tools are currently used in foundries providing 75% of all semiconductor production for fabless design companies globally. For example, working with GSS and their simulation tools has reduced the development time for IBM's next generation of CMOS technology by 1 year, representing significant savings in the 3-5 year technology development cycle.
The commercialisation of Quantum Cascade Lasers (QCL) and the associated novel fabrication processes developed at the University of Glasgow has provided Compound Semiconductor Technologies Global Ltd (CSTG) with a new foundry product supplying quantum cascade lasers for gas sensing, safety and security, and military applications. This resulted in 40% turnover growth from 2010-2012 and the company is now recognised as a global leader in QCLs and their fabrication. Based on University of Glasgow research, the company has created a manufacturing toolbox for the production of a wide variety of QCL chip designs. CSTG has also achieved a world first, manufacturing QCLs for systems that detect explosives at a safe distance and can counter heat-seeking missile attacks on aircraft.